

Joshua A Barocas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4385431/publications.pdf>

Version: 2024-02-01

63
papers

1,047
citations

430874

18
h-index

477307

29
g-index

65
all docs

65
docs citations

65
times ranked

1319
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. <i>American Journal of Public Health</i> , 2018, 108, 1675-1681.	2.7	109
2	Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. <i>Drug and Alcohol Dependence</i> , 2019, 200, 59-63.	3.2	103
3	Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. <i>Harm Reduction Journal</i> , 2014, 11, 1.	3.2	96
4	Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. <i>Clinical Infectious Diseases</i> , 2018, 67, 549-556.	5.8	53
5	Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2020, 70, 968-972.	5.8	45
6	Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2021, 72, 472-478.	5.8	42
7	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	5.9	37
8	Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. <i>Health Affairs</i> , 2017, 36, 2142-2150.	5.2	34
9	Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3661-e3669.	5.8	33
10	Business Not as Usual – Covid-19 Vaccination in Persons with Substance Use Disorders. <i>New England Journal of Medicine</i> , 2021, 384, e6.	27.0	31
11	Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e56-e64.	10.0	26
12	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108764.	3.2	25
13	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. <i>International Journal of Drug Policy</i> , 2019, 72, 160-168.	3.3	23
14	Hospitalization outcomes of people who use drugs: One size does not fit all. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 23-28.	2.8	23
15	Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e1112-e1119.	5.8	23
16	Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex. <i>JAMA Network Open</i> , 2020, 3, e2030201.	5.9	22
17	Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults. <i>JAMA Internal Medicine</i> , 2017, 177, 880.	5.1	21
18	High uptake of naloxone-based overdose prevention training among previously incarcerated syringe-exchange program participants. <i>Drug and Alcohol Dependence</i> , 2015, 154, 283-286.	3.2	19

#	ARTICLE	IF	CITATIONS
19	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Network Open, 2020, 3, e2029676.	5.9	17
20	Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug and Alcohol Dependence, 2020, 215, 108207.	3.2	16
21	Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in Russia. PLoS ONE, 2019, 14, e0218852.	2.5	14
22	Infective Endocarditis in Persons Who Use Drugs. Infectious Disease Clinics of North America, 2020, 34, 479-493.	5.1	14
23	Estimates of opioid use disorder prevalence from a regression-based multi-sample stratified capture-recapture analysis. Drug and Alcohol Dependence, 2020, 217, 108337.	3.2	13
24	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. Journal of Substance Abuse Treatment, 2020, 112, 42-48.	2.8	13
25	Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities. Journal of Substance Abuse Treatment, 2020, 118, 108103.	2.8	13
26	Time to SARS-CoV-2 PCR Clearance in Immunocompromising Conditions: Is Test-Based Removal From Isolation Necessary in Severely Immunocompromised Individuals?. Open Forum Infectious Diseases, 2021, 8, ofab164.	0.9	13
27	Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs. Open Forum Infectious Diseases, 2016, 3, ofw075.	0.9	12
28	Case 21-2020: A 66-Year-Old Homeless Man with Covid-19. New England Journal of Medicine, 2020, 383, 170-178.	27.0	12
29	Addressing the COVID-19 Pandemic Among Persons Experiencing Homelessness: Steps to Protect a Vulnerable Population. Journal of General Internal Medicine, 2021, 36, 1416-1417.	2.6	12
30	Advance directives among people living with HIV: room for improvement. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 370-377.	1.2	10
31	Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction, 2021, 116, 2790-2800.	3.3	9
32	Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12256.	3.7	9
33	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108336.	3.2	8
34	Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. International Journal of Drug Policy, 2021, 94, 103198.	3.3	8
35	Can I Safely Discharge a Patient with a Substance Use Disorder Home with a Peripherally Inserted Central Catheter?. , 2022, 1, .		8
36	A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto. Public Health Reports, 2021, 136, 532-537.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. <i>International Journal of Drug Policy</i> , 2021, 96, 103469.	3.3	7
38	Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use-associated Infective Endocarditis. <i>JAMA Network Open</i> , 2022, 5, e220541.	5.9	7
39	Prevalence of Covid-19 Infection and Subsequent Cohorting in a Residential Substance Use Treatment Program in Boston, MA. <i>Journal of Addiction Medicine</i> , 2020, 14, e261-e263.	2.6	6
40	Caring for COVID-19's Most Vulnerable Victims: a Safety-Net Hospital Responds. <i>Journal of General Internal Medicine</i> , 2021, 36, 1006-1010.	2.6	6
41	Factors associated with opioid-involved overdose among previously incarcerated people in the U.S.: A community engaged narrative review. <i>International Journal of Drug Policy</i> , 2022, 100, 103534.	3.3	6
42	USPSTF's Hepatitis C Screening Recommendation—A Necessary Step to Tackling an Evolving Epidemic. <i>JAMA Network Open</i> , 2020, 3, e200538.	5.9	5
43	Implementation of a Recuperation Unit and Hospitalization Rates Among People Experiencing Homelessness With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e212826.	5.9	5
44	Commentary on Irvine et al. (2019): Barriers to implementing a successful roadmap for preventing opioid-related overdose deaths. <i>Addiction</i> , 2019, 114, 1614-1615.	3.3	4
45	Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. <i>Addiction</i> , 2022, , .	3.3	4
46	Crisis stabilization units for jail diversion: A preliminary assessment of patient characteristics and outcomes. <i>Psychological Services</i> , 2022, 19, 630-636.	1.5	3
47	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 2450-2461.	3.3	3
48	Initiation of HIV pre-exposure prophylaxis among youth in the United States, 2015–2018. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 431-436.	1.2	3
49	Commentary on Jones et al. (2020): Using indirect estimation methods of drug use prevalence to address racial and ethnic health disparities. <i>Addiction</i> , 2020, 115, 2405-2406.	3.3	2
50	It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1401-1403.	5.8	2
51	Editorial Commentary: Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2017, 64, 100-101.	5.8	1
52	Assessment of Oropharyngeal Specimens for Discontinuation of Transmission-Based COVID-19 Precautions. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa382.	0.9	1
53	Housing Is an Essential Part of Health Care—Treat Them and House Them. <i>JAMA Network Open</i> , 2021, 4, e210635.	5.9	1
54	The Urgent Public Health Need to Develop Crisis Standards of Housing: Lessons From the COVID-19 Pandemic. <i>American Journal of Public Health</i> , 2021, 111, 1207-1209.	2.7	1

#	ARTICLE	IF	CITATIONS
55	Behavioral Risk Factors for HIV Infection in Hospitalized Persons Who Co-use Stimulants and Opioids. <i>AIDS and Behavior</i> , 2022, 26, 1047-1055.	2.7	1
56	Healthcare Providers' Views on Hepatitis C Testing and Counseling Among Sexual Partners of Hepatitis C-Infected Persons. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e151-e153.	0.3	1
57	An Economic Analysis of the Cost of a Regional Crisis Stabilization Unit. <i>Journal of Correctional Health Care</i> , 2021, , .	0.5	1
58	1608 Low rates of advance directive completion among HIV-infected patients: a retrospective analysis. <i>Open Forum Infectious Diseases</i> , 2014, 1, S429-S429.	0.9	0
59	1946. Heterogeneous Hospitalization Outcomes of People Who Use Drugs: The Type of Drug(s) Used Matters. <i>Open Forum Infectious Diseases</i> , 2018, 5, S561-S561.	0.9	0
60	2232. Zinc deficiency and advanced liver fibrosis among HIV/HCV co-infected persons in Russia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S660-S660.	0.9	0
61	100-100-100: a new, ambitious treatment target to end the HIV and hepatitis C epidemics. <i>Lancet Public Health</i> , The, 2022, 7, e98-e99.	10.0	0
62	58. Cost-Effectiveness of Emerging Antibiotic Strategies for the Treatment of Drug-Use Associated Infective Endocarditis. <i>Open Forum Infectious Diseases</i> , 2021, 8, S40-S40.	0.9	0
63	Stimulant-related incident surveillance using emergency medical service records in Massachusetts, 2013-2020.. <i>Drug and Alcohol Dependence</i> , 2022, 235, 109460.	3.2	0